Roth Affirms Bio Blast Pharma (ORPN) at 'Buy'; Plenty of Catalysts Ahead in Next 12 - 18 Months
Tweet Send to a Friend
Roth Capital affirms Bio Blast Pharma (Nasdaq: ORPN) at Buy with a price target of $18 followign the company's Q4 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
